Boston, MA 08/25/2014 (wallstreetpr) – According to reports the leading marketer, manufacturer and developer of proprietary clinical grade hypothermic storage products BioLife Solutions Inc (NASDAQ:BLFS) announced the adoption of CryoStor bio-preservation media products and HypoThermosol. The management of BLFS estimates that the products of the company are now incorporated into the storage, collection, shipping, patient administration and freezing processes of novel cell-based regenerative medicine therapies, products and around 130 customer clinical trials.
Road ahead:
Further details of these clinical trials include-
- More than sixty phase II trials
- More than twelve phase III trials
- All the disease states and large patient populations are covered by some of the trials like heart disease, various cancers, movement loss, vision loss, MS and stroke
- The company understands its responsibility towards cancer; therefore more than twelve people are working to make cell-based immunotherapies commercial.
- When it comes to the expected annual revenue per clinical trial stage product can vary from $500,000 to $2,000,000.
When reporters tried to ask questions from Mike Rice, BioLife Solutions Inc (NASDAQ:BLFS)’s President & CEO, he said, “Our company has increased the pace of adoption of adoption of our clinical grade bio-preservation media products over the last few years.” All the senior, as well as junior management employees of the company seemed quite happy after BLFS announced the adoption of HypoThermosol and CryoStor. The company has done pretty well over the past two years in terms of customer clinical trials. The numbers of customer clinical trials that BioLife Solutions Inc (NASDAQ:BLFS) had in 2012 were not more than 50, while today it has around 130 customer clinical trials which are amazing. The initiatives taken by BLFS over these years have increased the literacy level of the people about medicine market which is very satisfying for the top management of the company. On behalf of the entire management, Rice said that BioLife Solutions Inc (NASDAQ:BLFS) would continue helping the industry in coming months as well.
